Behavior of Vulvar Cancer over a 16-year Period at the National Cancer Institute (Colombia)

Authors

  • Mónica Medina Instituto Nacional de Cancerología
  • Ricardo Sánchez Instituto Nacional de Cancerología
  • Natascha Ortíz Instituto Nacional de Cancerología
  • Alexánder Rodríguez Clínica Medellín
  • Simón Oróstegui Universidad Autónoma de Bucaramanga

Keywords:

Vulvar neoplasms, prognosis, treatment outcome, mortality, cohort studies
Abstract Authors References How to Cite

Abstract

Objective: To describe patient mortality among patients with vulvar cancer at the National Cancer Institute of Colombia (INC).
Materials and Methods: Retrospective cohort study among vulvar cancer patients at the INC from 1990-2006. Survival estimated by Kaplan-Meyer; comparison with logarithmic trial rankings.
Results: 303 patients were diagnosed with vulvar cancer, including. One hundred and ninety cases fulfilled inclusion criteria. Average age, 59 (± 17,4). Most frequent symptoms: mass (42%), itch (31%). Most frequent histological types: squamous cell carcinoma (78%), melanoma (9%). Distribution according to stage: I, 14, 18%; II, 27, 61%; I I I, 44, 78%; IV, 13, 43%. Most frequent surgery, radical vulvectomy (51%). Treatements included: only surgery (55,2%); surgery and radiotherapy (18,9%); only radiotherapy (13,6%); radiotherapy and concomitant chemotherapy (7,8%); neoadyuvant chemotherapy and radiotherapy (3,6%); and only chemotherapy (1,5%). Chemotherapy schemes consisted of 5 fluoracil and mitomycin; cisplatin and 5 fluoracil. Median follow-up was 345 days (0-4,141). Mortality rate was 15, 95 deaths/100,000 women/day. There was a significant difference in mortality depending upon FIGO ( x2 (3)=9,7, p=0,02) and complete response to treatment (greater mortality in the non-response group, x2 (1)=27,4, p=0,000).
Conclusions: Significant variables contributing to mortality were FIGO, age and non-therapeutic response. Surgical treatment was very frequent considering the large number of advanced cases, thus contradicting the current trend towards chemoradiation.

Author Biographies

Mónica Medina, Instituto Nacional de Cancerología

Instituto Nacional de Cancerología. Bogotá, Colombia.

Ricardo Sánchez, Instituto Nacional de Cancerología

Instituto Nacional de Cancerología. Bogotá, Colombia.
Universidad Nacional de Colombia. Bogotá, Colombia.

Natascha Ortíz, Instituto Nacional de Cancerología

Instituto Nacional de Cancerología. Bogotá, Colombia.

Alexánder Rodríguez, Clínica Medellín

SaludCoop, Clínica Medellín. Medellín, Colombia.

Simón Oróstegui, Universidad Autónoma de Bucaramanga

Universidad Autónoma de Bucaramanga. Bucaramanga, Colombia.

References

Van der Velden J, Van lindert ACM, Gimbrere CFH, Gimbrere CH, Oosting H, Heintz AP. Epidemiologic data on vulvar cancer: Comparison of hospital with populationbased data. Gynecol Oncol. 1996;62(3):379-83.

https://doi.org/10.1006/gyno.1996.0252

Ghurani GB, Penalver MA. An update on vulvar cancer. Am J Obstet Gynecol. 2001;185(2): 294-9.

https://doi.org/10.1067/mob.2001.117401

Mitchell M, Prasad C, Silva E, Rutledge FN, McArthur MC, Crum CP. Second genital primary squamous neoplasms in vulvar carcinoma:viral and histopathologic correlates. Obstet Gynecol. 1993;81(1):13-8.

Orjuela R, Lopez Escobar G. Tumores malignos de la vulva. Rev Colomb Obstet Ginecol. 1952;3(1):9-39.

Duarte A, Gaitán, Palau M. Cáncer de la vulva a propósito de 181 historias del Instituto Nacional de Cancerología. Rev Colomb Obstet Ginecol. 1970;21(3):233-48.

Anastasiadis P, Skaphida P, Koutlaki N, Boli A, Galazios G, Liberis V. Trends in epidemiology of preinvasive and invasive vulvar neoplasias 13 year retrospective analysis in Thrace, Greece. Arch Gynecol Obstet. 2000;264(2):74-9.

https://doi.org/10.1007/s004040000083

Coleman RL, Santoso JT. Vulvar carcinoma. Curr Treat Options Oncol. 2000;1(2):177-90.

https://doi.org/10.1007/s11864-000-0063-4

Tyring S. Vulvar squamous cell carcinoma: Guidelines for early diagnosis and treatment. Am J Obstet Gynecol. 2003;189(3 Suppl):S17-23.

https://doi.org/10.1067/S0002-9378(03)00792-0

Malfetano J. Cáncer de vulva. 2 ed. En: Piver MS (editor). Oncología ginecológica. Madrid: Marban; 2000. p. 215-244.

Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cáncer. J Clin Oncol. 2008;26(6):884-9.

https://doi.org/10.1200/JCO.2007.14.0566

Douay-Hauser N, Akerman G, Tulpin L, Morel O, Malartic C, Desfeux P, et al. Sentinel node biopsy in vulvar cancer. Bull Cancer. 2008;95(7):701-6.

Hampl M, Hantschmann P, Michels W, Hillemanns P. Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Gynecol Oncol. 2008;111(2):282-8.

https://doi.org/10.1016/j.ygyno.2008.08.007

Frumovitz M, Levenback CF. Lymphatic mapping and sentinel node biopsy in vulvar, vaginal, and cervical cancers. Oncology (Williston Park). 2008;22(5):529-36; discussion 538-9, 542-3.

Oonk MH, van Os MA, de Bock GH, de Hullu JA, Ansink AC, van der Zee AG. A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy. Gynecol Oncol. 2009;113(3):301-5. Epub 2009 Mar 17.

https://doi.org/10.1016/j.ygyno.2008.12.006

Stroup AM, Harlan LC, Trimble EL. Demographic, clinical and treatment trends among women diagnosed with vulvar cáncer in the United States. Gynecol Oncol. 2008;108(3):577-83.

https://doi.org/10.1016/j.ygyno.2007.11.011

Landrum LM, Skaggs v, Gould N, Walker JL, McMeekin DS. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. Gynecol Oncol. 2008;108(3):584-90.

https://doi.org/10.1016/j.ygyno.2007.11.010

Gusberg SB, Runowickz CD. Gynecologyc cancers. In: Holleb AI, Fink DJE, Murphy GP (editors). Textbook of clinical oncology. Atlanta: American Cancer Society; 1991. p. 481-97.

Hopkins MP, Nemunaitis-Keller J. Carcinoma of the vulva. Ostet Gynecol Clin North Am. 2001;28(4):791-804.

https://doi.org/10.1016/S0889-8545(05)70236-9

Stehman F, Look K. Carcinoma of the vulva. Obstet Gynecol. 2006;107(3):719-33.

https://doi.org/10.1097/01.AOG.0000202404.55215.72

Mc Millan HM, Martin F, Walsh TA, Boyd WD, Coughlan BM. Vulval cancer, 1992-2002 audit--multidisciplinary care and prognostic factors. Ir Med J. 2006;99(8):234-6.

Raspagliesi F, Hanozet F, Ditto A, Solima E, Zanaboni F, Vecchione F. Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. Gynecol Oncol. 2006;102(2):333-7.

https://doi.org/10.1016/j.ygyno.2005.12.027

Whitcomb BP. Gynecologic malignancies. Surg Clin North Am. 2008;88(2):301-17.

https://doi.org/10.1016/j.suc.2008.01.004

How to Cite

[1]
Medina, M. et al. 2009. Behavior of Vulvar Cancer over a 16-year Period at the National Cancer Institute (Colombia). Revista Colombiana de Cancerología. 13, 1 (Mar. 2009), 22–28.

Downloads

Download data is not yet available.

Downloads

Published

2009-03-01

Issue

Vol. 13 No. 1 (2009)

Section

Research/original articles

License

Todos los derechos reservados.